Roche Diagnostics posted CHF 6.735 billion (US$8.58 billion) in global revenue, up 3% year-over-year. Abbott Diagnostics surged 24.7% to US$5.272 billion. Danaher Diagnostics grew 2.6% to US$4.883 billion.。 Roche's China diagnostics revenue hit CHF 749 million (US$954 million) in H1 2026, a 15% decline at constant exchange rates. China's share of Roche Diagnostics' global sales fell from 13.1% to 11.1%.。 The company pointed to "healthcare pricing reforms in China" — the official euphemism for volume-based procurement (VBP). In 2025, Roche's China diagnostics sales plunged 24% for the full year. Core lab oncology reagent sales were cut in half.。
购买数据产品
400-9696-311 转1
数据与AI定制业务
400-9696-311 转3
商务合作及其他问题
400-9696-311 转4
投诉及建议
400-9696-311 转5
关注摩熵医药公众号
随时查阅行业资讯
摩熵医药数据小程序
掌上数据查询系统
川公网安备51019002008863号
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
收藏
登录后参与评论
暂无评论